Stock ADIL ADIAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Market Closed - Nasdaq
Other stock markets
 21:00:00 15/05/2024 BST 		5-day change 1st Jan Change
1.42 USD -1.39% Intraday chart for Adial Pharmaceuticals, Inc. -10.69% -23.66%
04-22 Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder MT
04-12 Top Premarket Decliners MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder
Top Premarket Decliners
Top Midday Gainers
Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Top Premarket Decliners
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell
US Futures Remain Flat as Investors Await Raft of Economic Data
Top Midday Gainers
Adial Pharmaceuticals Secures US Patent Allowance for AD04, Genetic Diagnostic Combination
Adial Pharmaceuticals Receives New Patent Notice of Allowance from the United States Patent and Trademark Office
Adial Pharmaceuticals Appoints Tony Goodmans as Chief Operating Officer
Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer
Top Premarket Gainers
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Adial Pharmaceuticals Awarded Patent Combining Use of Genetic Diagnostic With AD04 to Treat Alcohol, Drug Dependence
Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence
Adial Pharmaceuticals, Inc. Announces Board Changes
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADIL Stock
  4. News Adial Pharmaceuticals, Inc.
  5. Other languages